文献速递慢性肾脏病肾小球疾病

卡格列净对白蛋白尿及个体干预前eGFR斜率变化的影响:CANPIONE随机试验

A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
PubMed 文献 · Kidney Int · 2024-08-30

CANPIONE 是一项随机、平行分组、开放标签试验,纳入 98 例 2 型糖尿病伴微量白蛋白尿且 eGFR≥45 ml/min/1.73m2 的患者,比较卡格列净与指南推荐治疗(除外 SGLT2 抑制剂)。结果显示卡格列净显著降低 UACR,组间差异为 -30.8%(95%CI -42.6 至 -16.8),并使 eGFR 斜率变化组间差异达 4.4(95%CI 1.6 至 7.3)ml/min/1.73m2/年。

要点

  • 卡格列净较对照显著降低 2 型糖尿病伴微量白蛋白尿患者的 UACR。
  • 卡格列净使 eGFR 斜率变化组间差异为 4.4 ml/min/1.73m2/年。
  • 个体干预前 eGFR 斜率变化或可用于早期 CKD 肾脏保护疗效评估。

核心结论

  • 卡格列净可降低 2 型糖尿病伴微量白蛋白尿患者的白蛋白尿并改善个体 eGFR 下降的自然病程。
  • 个体内 eGFR 斜率变化可能是评估早期 CKD 新疗法肾脏保护潜力的新方法。

研究设计与样本

  • 随机、平行分组、开放标签临床试验(CANPIONE 研究),纳入 98 例受试者,96 例至少接受一次研究治疗。
  • 纳入标准为 2 型糖尿病、UACR 50 至不足 300 mg/g、eGFR 至少 45 ml/min/1.73m2,1:1 随机接受卡格列净或指南推荐治疗(除外 SGLT2 抑制剂)。
  • 第一主要结局为 UACR 相对基线几何均值百分比变化,第二主要结局为 eGFR 斜率变化。

主要发现

  • 卡格列净组 log 转换后几何均值 UACR 相对基线的最小二乘均值变化显著大于对照组,组间差异为 -30.8%(95%CI -42.6 至 -16.8)。
  • eGFR 斜率变化(慢性斜率减干预前斜率)的组间差异(卡格列净组减对照组)为 4.4(95%CI 1.6 至 7.3)ml/min/1.73m2/年。
  • 在 eGFR 下降更快的受试者中,上述 eGFR 斜率变化的组间差异更为明显。

关键数值与推荐

  • UACR 组间差异为 -30.8%(95%CI -42.6 至 -16.8)。
  • eGFR 斜率变化组间差异为 4.4(95%CI 1.6 至 7.3)ml/min/1.73m2/年。

临床怎么用

  • 对 2 型糖尿病伴微量白蛋白尿且 eGFR≥45 ml/min/1.73m2 的患者,卡格列净可降低白蛋白尿并减缓 eGFR 下降。
  • 在早期 CKD 中可考虑采用个体干预前 eGFR 斜率变化作为评估肾脏保护疗效的指标。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Demonstrating drug efficacy in slowing kidney disease progression requires large clinical trials when targeting participants with an early stage of chronic kidney disease (CKD). In this randomized, parallel-group, open-labeled trial (CANPIONE study), we assessed the effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin using the individual's change in estimated glomerular filtration rate (eGFR) slope before (pre-intervention slope) and during treatment (chronic slope). We randomly assigned (1:1) participants with type 2 diabetes, urinary albumin-to-creatinine ratio (UACR) of 50 to under 300 mg/g, and an eGFR of at least 45 ml/min/1.73m2 to receive canagliflozin or guideline-recommended treatment except for SGLT2 inhibitors (control). The first and second primary outcomes were the geometric mean percentage change from baseline in UACR and the change in eGFR slope, respectively. Of 98 randomized participants, 96 received at least one study treatment. The least-squares mean change from baseline in log-transformed geometric mean UACR was significantly greater in the canagliflozin group than the control group (between group-difference, -30.8% (95% confidence interval -42.6 to -16.8). The between-group difference (canagliflozin group - control group) of change in eGFR slope (chronic - pre-intervention) was 4.4 (1.6 to 7.3) ml/min/1.73 m2 per year, which was more pronounced in participants with faster eGFR decline. In summary, canagliflozin reduced albuminuria and the participant-specific natural course of eGFR decline in participants with type 2 diabetes and microalbuminuria. Thus, the CANPIONE study suggests that the within-individual change in eGFR slope may be a novel approach to determine the kidney protective potential of new therapies in early stages of CKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Miyamoto S, Heerspink HJL, de Zeeuw D, et al. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney Int. 2024. PMID: 39216659. doi:10.1016/j.kint.2024.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。